Search Follow us
Refine By

Stock Exchange

Analyst

Type of Publication

anthera

1 - 5 of 5
Sort by: popularity | newest
Page  of 1
Anthera Pharmaceuticals

Upcoming readouts on all programs

QuickView | Pharmaceutical & healthcare | 19 Apr 2016

Anthera is focused on the rational design of biologic products based on established mechanisms. The most advanced product is Sollpura, a pancreatic enzyme replacement for cystic fibrosis (CF) patients and other chronic pancreatitis, representing a $1bn market. Pivotal results are expected YE16/Q1'17. The company is also developing blisibimod, a novel peptibody BAFF inhibitor in the same class as Benlysta but significantly more potent, for the treatment of severe lupus and IgA nephropathy, with near-term clinical readouts in Q316 and Q216 respectively.

Trillium Therapeutics

Edison healthcare quarterly: Immunotherapy takes centre stage

Sector Commentary: | Pharmaceutical & healthcare | 31 Jul 2013

-

Merrimack Pharmaceuticals

Edison healthcare quarterly: German (drug) reformation

Sector Commentary: | Pharmaceutical & healthcare | 10 Apr 2013

-

Cytos Biotechnology

Edison healthcare quarterly: Crisis? What crisis?

Sector Commentary: | Pharmaceutical & healthcare | 30 Aug 2012

-

Anthera Pharmaceuticals

Pipeline validation zone

QuickView | Pharmaceutical & healthcare | 24 Feb 2012

Anthera is facing a pivotal and potentially transformational few weeks, with interim efficacy analysis of clinical trials testing its two most advanced pipeline candidates due by the middle of March 2012. Data Safety Monitoring Board (DSMB) reviews, of varespladib's Phase III for acute coronary syndromes (ACS) and blisibimod's Phase IIb for lupus, could result in early termination of the trials if overwhelming treatment benefits are seen. High efficacy bars have been set so a positive outcome in either study could spark significant share price gains and serious partnering interest.